Abstract
Release of cell free DNA (cfDNA) from damaged or dead cells routinely occurs in normal physiology. Recently, cfDNA has emerged as an essential biomarker in cardiovascular disease (CVD) of potential prognostic and diagnostic significance. Within the last decade, significant research efforts have been devoted to uncovering the mechanisms mediating cfDNA release and its outcome-predicting ability. The current review focuses on the pathways for cfDNA release in myocardial infarction, heart failure and hypertension, and discusses implementation of cfDNA monitoring to assess the overall development of these disease states and predict future complications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 145-150 |
| Number of pages | 6 |
| Journal | Clinica Chimica Acta |
| Volume | 503 |
| DOIs | |
| State | Published - Apr 2020 |
Bibliographical note
Funding Information:This work was supported by the National Institute of Health (NIDDK) R00DK105160 to DVI, (NIDA) U54DA016511 to KYD-P and DVI, and the Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development Award IK2BX003922 to KYD-P. This work was also financially supported, in part, by the 2019 S&R Foundation Ryuji Ueno Award that was bestowed upon KYD-P by the American Physiological Society. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Veterans Administration, or the American Physiological Society.
Funding Information:
This work was supported by the National Institute of Health (NIDDK) R00DK105160 to DVI, (NIDA) U54DA016511 to KYD-P and DVI, and the Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development Award IK2BX003922 to KYD-P. This work was also financially supported, in part, by the 2019 S&R Foundation Ryuji Ueno Award that was bestowed upon KYD-P by the American Physiological Society. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Veterans Administration, or the American Physiological Society.
Publisher Copyright:
© 2020
Keywords
- Cardiovascular disease
- Inflammation
- MMPs
- cfDNA
